

# Global MEK Inhibitors Market, Drug Sales & Clinical Trials insight 2026

<https://marketpublishers.com/r/G813F3A1C176EN.html>

Date: October 2021

Pages: 172

Price: US\$ 2,400.00 (Single User License)

ID: G813F3A1C176EN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global MEK Inhibitors Market, Drug Sales & Clinical Trials insight 2026 Report Analysis & Data Highlights:

Research Methodology

Global & Regional Market Analysis

Global MEK Inhibitors Market Opportunity Assessment: > USD 3 Billion

Market & Drug Sales Insight 2020 Till 2026

Approved Drug In Market: 4 Drugs

Approved MEK Drug Patent, Price & Sales insight 2020 Till 2026

Future Market Assessment By Indication Till 2026

Ongoing Clinical Trials Assessment by Status, Phase & Region

Key Market Dynamics

Competitor Landscape

The advances in the field of biotechnology and bioinformatics have enabled the researchers for the identification of genes or pathways which have critical role in the development and progression of this disease. The enhanced knowledge by scientists and their extensive efforts have led to the development of novel targeted therapies which have shown to significantly enhance the survival rates in patients.

The identification of mitogen activated protein kinase (MAPK) signaling pathway and its critical role in the regulation of diverse cellular activities in the development of cancer including cell proliferation, survival, and differentiation have drawn the interest the researchers to inhibit the pathway as an alternative in the management of cancer. The MEK inhibitors were developed to specifically target the Ras/Ref/Me/Erk signaling pathway thus inhibiting cell proliferation, and inducing apoptosis.

To date, four MEK inhibitors have entered into the market which has shown high adoption rates by BRAF mutated cancer patients, mainly in melanoma. In addition to this, several other MEK inhibitors are present in the clinical trials. The potential candidates in the pipeline are AZD8330, NX-179, HL-085, E6201, Mirdametinib and Refametinib. These drugs have shown encouraging clinical response in their early studies and are expected to enter the market during the forthcoming years.

Apart from melanoma, several ongoing clinical trials are also ongoing which are accessing the role of MEK inhibitors in other cancers including non-small cell lung cancer, breast cancer, thyroid cancer, ovarian cancers and others. It is expected that the coming years will witness expanded approval of the approved MEK inhibitors in other cancers which will further propel the growth of market. For instance, Mekinist is being evaluated in phase-III for management of ovarian cancer or Koselugo is in phase-III for NSCLC patients and is expected to gain approval by end of 2022.

The future will see a dominance of combination therapy in MEK inhibitors market attributable to its high efficacy in comparison to monotherapy. Combinations of MEK inhibitors and targeted therapies appear to have specific promise in the setting of acquired resistance to targeted therapy, a pervasive challenge in the era of precision medicine. Moreover, the robust response of MEK inhibitors in combination with BRAF inhibitors in clinical practice has shown to significantly improve the outcomes in patients.

Apart from combing MEK inhibitors with other pathway inhibitors, studies are investigating the effect of MEK inhibition on the immune environment of tumors. Many clinical trials combining MEK inhibitor with immunotherapeutic agents are currently ongoing and have shown promising preclinical data. The promising early results of

combinational treatment bring hope for further progress in the management of patients with cancer.

The overall MEK inhibitor market is highly competitive in nature, with leading players involved in regional expansion, partnerships, new product development, and research and development to increase market penetration. The key players in global MEK inhibitors market are Roche, Pfizer, AstraZeneca, Novartis, Cstone Therapeutics, and Ono Pharmaceuticals. Moreover, the pipeline of MEK inhibitors is highly crowded and the coming years will witness rapid approval of MEK inhibitors in management of wide range of cancers.

## Contents

### RESEARCH METHODOLOGY

#### 1. INTRODUCTION TO MEK INHIBITORS

#### 2. MEK INHIBITORS - MECHANISM OF ACTION

#### 3. GLOBAL MEK INHIBITORS MARKET OVERVIEW

##### 3.1 Current Market Scenario

##### 3.2 Key Drugs Candidates in Research & Development

##### 3.3 Future Market Opportunity

#### 4. GLOBAL MEK INHIBITORS MARKET TRENDS BY REGION

##### 4.1 US

##### 4.2 Europe

##### 4.3 China

##### 4.4 Japan

#### 5. GLOBAL MEK INHIBITORS CLINICAL TRIALS INSIGHT

##### 5.1 By Phase

##### 5.2 By Status

##### 5.3 By Region

#### 6. MEKINIST (TRAMETINIB) – CLINICAL & SALES INSIGHT

##### 6.1 Overview

##### 6.2 Patents & Assignees

##### 6.3 Dosage & Price Analysis

##### 6.4 Sales Analysis

#### 7. COTELLIC (COBIMETINIB) – CLINICAL & SALES INSIGHT

##### 7.1 Overview

##### 7.2 Patents & Assignees

##### 7.3 Dosage & Price Analysis

## 7.4 Sales Analysis

## **8. MEKTOVI (BINIMETINIB) – CLINICAL & SALES INSIGHT**

### 8.1 Overview

### 8.2 Patents & Assignees

### 8.3 Dosage & Price Analysis

### 8.4 Sales Analysis

## **9. KOSELUGO (SELUMITINIB) – CLINICAL & SALES INSIGHT**

### 9.1 Overview

### 9.2 Patents & Assignees

### 9.3 Dosage & Price Analysis

### 9.4 Sales Analysis

## **10. MEK INHIBITORS SALES FORECAST 2026**

### 10.1 Mekinist Sales Forecast

### 10.2 Cotellic Sales Forecast

### 10.3 Mektovi Sales Forecast

### 10.4 Koselugo Sales Analysis

## **11. MEK INHIBITORS MARKET OPPORTUNITY BY INDICATION**

### 11.1 Melanoma

### 11.2 Lung Cancer

### 11.3 Colorectal Cancer

### 11.4 Thyroid Cancer

### 11.5 Breast Cancer

## **12. GLOBAL MEK INHIBITORS CLINICAL TRIALS INSIGHT – ACTIVE TRIALS**

### 12.1 Research

### 12.2 Preclinical

### 12.3 Phase-I

### 12.4 Phase-I/II

### 12.5 Phase-II

### 12.6 Phase-II/III

12.7 Registered

### **13. MARKETED MEK INHIBITORS DRUGS CLINICAL INSIGHT**

### **14. GLOBAL MEK INHIBITORS MARKET FUTURE PERSPECTIVE**

### **15. GLOBAL MEK INHIBITORS MARKET DYNAMICS**

15.1 Favorable Market Parameters

15.2 Market Challenges

### **16. COMPETITIVE LANDSCAPE**

16.1 AstraZeneca

16.2 Bristol Myers Squibb

16.3 CStone Therapeutics

16.4 GlaxoSmithKline

16.5 Immuneering

16.6 Merck

16.7 NFlection Therapeutics

16.8 Novartis

16.9 Ono Pharmaceutical

16.10 Pfizer

16.11 Roche

16.12 SpringWorks Therapeutics

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Approved MEK Inhibitors
- Figure 2-1: MEK Inhibitors - Mechanism of Action
- Figure 2-2: Trametinib - Mechanism of Action in Combinational Therapy
- Figure 3-1: Global - Cancer Incidence (Million), 2020 & 2025
- Figure 3-2: Global - Cancer Deaths (Million), 2020 & 2025
- Figure 3-3: Global - MEK Inhibitor Market by Product (%), 2020
- Figure 3-4: Global - MEK Inhibitor Market by Product (%), H1'2021
- Figure 3-5: Global - MEK Inhibitor Market by Product (US\$ Million), 2020
- Figure 3-6: Global - MEK Inhibitor Market by Product (US\$ Million), H1'2021
- Figure 3-7: Global – MEK Inhibitor Market Size (US\$ Million), 2020 - 2026
- Figure 3-8: MEK Inhibitor Market by Region (US\$ Million), 2020
- Figure 3-9: MEK Inhibitor Market by Region (%), 2020
- Figure 3-10: ROW – MEK Inhibitor Market Size (US\$ Million), 2020 - 2026
- Figure 4-1: US - Cancer Incidence (Million), 2020 & 2025
- Figure 4-2: US - Cancer Deaths (Million), 2020 & 2025
- Figure 4-3: MEK Inhibitor Market – US vs. ROW (US\$ Million), 2020
- Figure 4-4: MEK Inhibitor Market - US vs. ROW (%), 2020
- Figure 4-5: US – MEK Inhibitor Market Size (US\$ Million), 2020 - 2026
- Figure 4-6: Europe - Cancer Incidence (Million), 2020 & 2025
- Figure 4-7: Europe - Cancer Deaths (Million), 2020 & 2025
- Figure 4-8: MET Inhibitor Market - Europe vs. ROW (US\$ Million), 2020
- Figure 4-9: MET Inhibitor Market - Europe vs. ROW (%), 2020
- Figure 4-10: Europe – MEK Inhibitors Market Size (US\$ Million), 2020 – 2026
- Figure 4-11: China - Cancer Incidence (Million), 2020 & 2025
- Figure 4-12: China - Cancer Deaths (Million), 2020 & 2025
- Figure 4-13: MET Inhibitor Market - China vs. ROW (US\$ Million), 2020
- Figure 4-14: MET Inhibitor Market - China vs. ROW (%), 2020
- Figure 4-15: China – MEK Inhibitors Market Size (US\$ Million), 2020 – 2026
- Figure 4-16: Japan - Cancer Incidence (Million), 2020 & 2025
- Figure 4-17: Japan - Cancer Deaths (Million), 2020 & 2025
- Figure 4-18: MET Inhibitor Market - Japan vs. ROW (US\$ Million), 2020
- Figure 4-19: MET Inhibitor Market - Japan vs. ROW (%), 2020
- Figure 4-20: Japan – MEK Inhibitors Market Size (US\$ Million), 2020 – 2026
- Figure 5-1: Global - MEK Inhibitors Clinical Insights by Phase (Number of Trials), September'2021

Figure 5-2: Global - MEK Inhibitors Clinical Trials Insights by Phase (%),  
September'2021

Figure 5-3: Global - MEK Inhibitors Clinical Trials Insights by Status (Number of Trials),  
September'2021

Figure 5-4: Global - MEK Inhibitors Clinical Trials Insights by Status (%),  
September'2021

Figure 5-5: MEK Inhibitors – Clinical Trials Insights by Region (Number of Trials),  
September'2021

Figure 5-6: North America – MEK Inhibitors Clinical Trials by Countries (Number of  
Trials), September'2021

Figure 5-7: MEK Inhibitors – Clinical Trials Insights by Region (%), September'2021

Figure 5-8: North America – MEK Inhibitors Clinical Trials by Countries (%),  
September'2021

Figure 6-1: US – Mekinist FDA Approval History by Indication

Figure 6-2: Mekinist – Approval Year by Region

Figure 6-3: US – Mekinist Patents Assigned by Assignees

Figure 6-4: US – Mekinist Patent Approval & Expiration Year

Figure 6-5: Mekinist – Patent Exclusivity by Region

Figure 6-6: Mekinist – Cost of Supply of 30 Tablets & Per Unit Cost of 0.5mg Oral Tablet  
(US\$), September'2021

Figure 6-7: Mekinist – Cost of Supply of 30 Tablets & Per Unit Cost of 2mg Oral Tablet  
(US\$), September'2021

Figure 6-8: Mekinist – Recommended Initial & Dose Reductions (mg/day)

Figure 6-9: Mekinist – Average Daily, Monthly & Annual Treatment Cost (US\$),  
September'2021

Figure 6-10: Global – Mekinist Annual Sales (US\$ Million), 2018 – 2020

Figure 6-11: US – Mekinist Annual Sales (US\$ Million), 2018 – 2020

Figure 6-12: ROW – Mekinist Annual Sales (US\$ Million), 2018 – 2020

Figure 6-13: Mekinist - Annual Sales by Region (US\$ Million), 2020

Figure 6-14: Mekinist - Annual Sales by Region (%), 2020

Figure 6-15: Global – Mekinist Quarterly Sales (US\$ Million), 2020

Figure 6-16: US – Mekinist Quarterly Sales (US\$ Million), 2020

Figure 6-17: ROW – Mekinist Quarterly Sales (US\$ Million), 2020

Figure 6-18: Global – Mekinist Quarterly Sales (US\$ Million), Q1 & Q2'2021

Figure 6-19: US – Mekinist Quarterly Sales (US\$ Million), Q1 & Q2'2021

Figure 6-20: Mekinist – Half Year Sales (US\$ Million) by Region, H1'2021

Figure 6-21: Mekinist – Half Year Sales by Region (%), 2021

Figure 7-1: Cotellic – Approval Year by Region

Figure 7-2: US – Cotellic Patent Approval & Expiration Year



Figure 7-3: Europe – Cotellic EMA Approval & Patent Exclusivity Year

Figure 7-4: Cotellic – Cost of Supply of 63 Tablets & Per Unit Cost of 20mg Oral Tablet (US\$), September'2021

Figure 7-5: Cotellic – Recommended Initial & Dose Reductions (mg/day)

Figure 7-6: Cotellic – Average Daily, Monthly & Annual Treatment Cost (US\$), September'2021

Figure 7-7: Global - Cotellic Annual Sales (CHF/US\$ Million), 2018 - 2020

Figure 7-8: US - Cotellic Annual Sales (CHF/US\$ Million), 2018 - 2020

Figure 7-9: Europe - Cotellic Annual Sales (CHF/US\$ Million), 2018 - 2020

Figure 7-10: ROW - Cotellic Annual Sales (CHF/US\$ Million), 2018 - 2020

Figure 7-11: Cotellic - Annual Sales by Region (CHF/US\$ Million), 2020

Figure 7-12: Cotellic - Annual Sales by Region (%), 2020

Figure 7-13: Global - Cotellic Quarterly Sales (CHF/US\$ Million), Q1 & Q2'2021

Figure 7-14: US - Cotellic Quarterly Sales (CHF/US\$ Million), Q1 & Q2'2021

Figure 7-15: Europe – Cotellic Quarterly Sales (CHF/US\$ Million), Q1 & Q2'2021

Figure 7-16: ROW - Cotellic Quarterly Sales (CHF/US\$ Million), Q1 & Q2'2021

Figure 7-17: Cotellic - Half Year Sales by Region (CHF/US\$ Million), H1'2021

Figure 7-18: Cotellic - Half Year Sales by Region (%), H1'2021

Figure 8-1: Mektovi – Approval Year by Region

Figure 8-2: Japan - Mektovi Approval Year by Indication

Figure 8-3: US – Mektovi Patents Assigned by Assignees

Figure 8-4: US – Mektovi Patent Approval & Expiration Year

Figure 8-5: Mektovi – Cost of Supply of 180 Tablets & Per Unit Cost of 15mg Oral Tablet (US\$), September'2021

Figure 8-6: Mektovi – Recommended Initial & Dose Reductions (mg/day)

Figure 8-7: Mektovi – Average Daily, Monthly & Annual Treatment Cost (US\$), September'2021

Figure 8-8: Global – Mektovi Annual Sales (US\$ Million), 2019 & 2020

Figure 8-9: Global – Mektovi Quarterly Sales (US\$ Million), 2020

Figure 8-10: Global – Mektovi Quarterly Sales (US\$ Million), Q1 & Q2'2021

Figure 9-1: Koselugo – Approval Year by Region

Figure 9-2: US – Koselugo Patent Approval & Expiration Year

Figure 9-3: Koselugo – Cost of Supply of 28 Capsules & Per Unit Cost of 10mg Oral Capsule (US\$), September'2021

Figure 9-4: Koselugo – Cost of Supply of 60 Capsules & Per Unit Cost of 10mg Oral Capsule (US\$), September'2021

Figure 9-5: Koselugo – Cost of Supply of 28 Capsules & Per Unit Cost of 25mg Oral Capsule (US\$), September'2021

Figure 9-6: Koselugo – Cost of Supply of 60 Capsules & Per Unit Cost of 25mg Oral

Capsule (US\$), September'2021

Figure 9-7: Global – Koselugo Quarterly Sales (US\$ Million), Q2-Q4'2020

Figure 9-8: Global – Koselugo Quarterly Sales (US\$ Million), Q1 & Q2'2021

Figure 10-1: Global - Mekinist Sales Forecast (US\$ Million), 2021-2026

Figure 10-2: US - Mekinist Sales Forecast (US\$ Million), 2021-2026

Figure 10-3: ROW - Mekinist Sales Forecast (US\$ Million), 2021-2026

Figure 10-4: Global - Cotellic Sales Forecast (US\$ Million), 2021-2026

Figure 10-5: US - Cotellic Sales Forecast (US\$ Million), 2021-2026

Figure 10-6: Europe - Cotellic Sales Forecast (US\$ Million), 2021-2026

Figure 10-7: ROW - Cotellic Sales Forecast (US\$ Million), 2021-2026

Figure 10-8: Global – Mektovi Sales Forecast (US\$ Million), 2021 - 2026

Figure 10-9: Global – Koselugo Sales Forecast (US\$ Million), 2021 - 2026

Figure 11-1: Global – Estimated Melanoma Incidences, 2020 - 2026

Figure 11-2: Global – MEK Inhibitor Therapy Adoption Rate by 2% of Total Melanoma Patients, 2021-2026

Figure 11-3: Global – MEK Inhibitor Therapy Adoption Rate by 4% of Total Melanoma Patients, 2021-2026

Figure 11-4: Global – MEK Inhibitor Therapy Adoption Rate by 6% of Total Melanoma Patients, 2021-2026

Figure 11-5: Global – MEK Inhibitor Therapy Adoption Rate by 8% of Total Melanoma Patients, 2021-2026

Figure 11-6: Global – MEK Inhibitor Therapy Adoption Rate by 10% of Total Melanoma Patients, 2021-2026

Figure 11-7: Global – MEK Inhibitor Therapy Adoption Rate by 12% of Total Melanoma Patients, 2021-2026

Figure 11-8: Global – MEK Inhibitor Therapy Adoption Rate by 14% of Total Melanoma Patients, 2021-2026

Figure 11-9: Global – MEK Inhibitor Therapy Adoption Rate by 16% of Total Melanoma Patients, 2021-2026

Figure 11-10: Global – MEK Inhibitor Therapy Adoption Rate by 18% of Total Melanoma Patients, 2021-2026

Figure 11-11: Global – MEK Inhibitor Therapy Adoption Rate by 20% of Total Melanoma Patients, 2021-2026

Figure 11-12: Global – Estimated Lung Cancer Incidences, 2020 - 2026

Figure 11-13: Global – MEK Inhibitor Therapy Adoption Rate by 2% of Total Lung Cancer Patients, 2021-2026

Figure 11-14: Global – MEK Inhibitor Therapy Adoption Rate by 4% of Total Lung Cancer Patients, 2021-2026

Figure 11-15: Global – MEK Inhibitor Therapy Adoption Rate by 6% of Total Lung

Cancer Patients, 2021-2026

Figure 11-16: Global – MEK Inhibitor Therapy Adoption Rate by 8% of Total Lung Cancer Patients, 2021-2026

Figure 11-17: Global – MEK Inhibitor Therapy Adoption Rate by 10% of Total Lung Cancer Patients, 2021-2026

Figure 11-18: Global – MEK Inhibitor Therapy Adoption Rate by 12% of Total Lung Cancer Patients, 2021-2026

Figure 11-19: Global – MEK Inhibitor Therapy Adoption Rate by 14% of Total Lung Cancer Patients, 2021-2026

Figure 11-20: Global – MEK Inhibitor Therapy Adoption Rate by 16% of Total Lung Cancer Patients, 2021-2026

Figure 11-21: Global – MEK Inhibitor Therapy Adoption Rate by 18% of Total Lung Cancer Patients, 2021-2026

Figure 11-22: Global – MEK Inhibitor Therapy Adoption Rate by 20% of Total Lung Cancer Patients, 2021-2026

Figure 11-23: Global – Estimated Colorectal Cancer Cases, 2020-2026

Figure 11-24: Global – MEK Inhibitor Therapy Adoption Rate by 1% of Total Colorectal Cancer Patients, 2021-2026

Figure 11-25: Global – MEK Inhibitor Therapy Adoption Rate by 2% of Total Colorectal Cancer Patients, 2021-2026

Figure 11-26: Global – MEK Inhibitor Therapy Adoption Rate by 3% of Total Colorectal Cancer Patients, 2021-2026

Figure 11-27: Global – MEK Inhibitor Therapy Adoption Rate by 4% of Total Colorectal Cancer Patients, 2021-2026

Figure 11-28: Global – MEK Inhibitor Therapy Adoption Rate by 5% of Total Colorectal Cancer Patients, 2021-2026

Figure 11-29: Global – MEK Inhibitor Therapy Adoption Rate by 6% of Total Colorectal Cancer Patients, 2021-2026

Figure 11-30: Global – MEK Inhibitor Therapy Adoption Rate by 7% of Total Colorectal Cancer Patients, 2021-2026

Figure 11-31: Global – MEK Inhibitor Therapy Adoption Rate by 8% of Total Colorectal Cancer Patients, 2021-2026

Figure 11-32: Global – MEK Inhibitor Therapy Adoption Rate by 9% of Total Colorectal Cancer Patients, 2021-2026

Figure 11-33: Global – MEK Inhibitor Therapy Adoption Rate by 10% of Total Colorectal Cancer Patients, 2021-2026

Figure 11-34: Global – Estimated Thyroid Cancer Cases, 2020-2026

Figure 11-35: Global – MEK Inhibitor Therapy Adoption Rate by 1% of Total Thyroid Cancer Patients, 2021-2026

Figure 11-36: Global – MEK Inhibitor Therapy Adoption Rate by 2% of Total Thyroid Cancer Patients, 2021-2026

Figure 11-37: Global – MEK Inhibitor Therapy Adoption Rate by 3% of Total Thyroid Cancer Patients, 2021-2026

Figure 11-38: Global – MEK Inhibitor Therapy Adoption Rate by 4% of Total Thyroid Cancer Patients, 2021-2026

Figure 11-39: Global – MEK Inhibitor Therapy Adoption Rate by 5% of Total Thyroid Cancer Patients, 2021-2026

Figure 11-40: Global – MEK Inhibitor Therapy Adoption Rate by 6% of Total Thyroid Cancer Patients, 2021-2026

Figure 11-41: Global – MEK Inhibitor Therapy Adoption Rate by 7% of Total Thyroid Cancer Patients, 2021-2026

Figure 11-42: Global – MEK Inhibitor Therapy Adoption Rate by 8% of Total Thyroid Cancer Patients, 2021-2026

Figure 11-43: Global – MEK Inhibitor Therapy Adoption Rate by 9% of Total Thyroid Cancer Patients, 2021-2026

Figure 11-44: Global – MEK Inhibitor Therapy Adoption Rate by 10% of Total Thyroid Cancer Patients, 2021-2026

Figure 11-45: Global – Estimated Thyroid Cancer Cases, 2020-2026

Figure 11-46: Global – MEK Inhibitor Therapy Adoption Rate by 1% of Total Breast Cancer Patients, 2021-2026

Figure 11-47: Global – MEK Inhibitor Therapy Adoption Rate by 2% of Total Breast Cancer Patients, 2021-2026

Figure 11-48: Global – MEK Inhibitor Therapy Adoption Rate by 3% of Total Breast Cancer Patients, 2021-2026

Figure 11-49: Global – MEK Inhibitor Therapy Adoption Rate by 4% of Total Breast Cancer Patients, 2021-2026

Figure 11-50: Global – MEK Inhibitor Therapy Adoption Rate by 5% of Total Breast Cancer Patients, 2021-2026

Figure 11-51: Global – MEK Inhibitor Therapy Adoption Rate by 6% of Total Breast Cancer Patients, 2021-2026

Figure 11-52: Global – MEK Inhibitor Therapy Adoption Rate by 7% of Total Breast Cancer Patients, 2021-2026

Figure 11-53: Global – MEK Inhibitor Therapy Adoption Rate by 8% of Total Breast Cancer Patients, 2021-2026

Figure 11-54: Global – MEK Inhibitor Therapy Adoption Rate by 9% of Total Breast Cancer Patients, 2021-2026

Figure 11-55: Global – MEK Inhibitor Therapy Adoption Rate by 10% of Total Breast Cancer Patients, 2021-2026

Figure 12-1: Global – Number of MEK Inhibitors Drug In Clinical Trials By Phase'September'2021

Figure 15-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025

Figure 15-2: Global - MET Inhibitor Market Favorable Parameters

Figure 15-3: US – Average Monthly Cost & Annual Cost of Treatment with Vemurafenib & Cobimetinib (US\$), 2020

Figure 15-4: US – Average Monthly Cost & Annual Cost of Treatment with Dabrafenib & Trametinib (US\$), 2020

Figure 15-5: Global - MEK Inhibitor Market Challenges

## I would like to order

Product name: Global MEK Inhibitors Market, Drug Sales & Clinical Trials insight 2026

Product link: <https://marketpublishers.com/r/G813F3A1C176EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G813F3A1C176EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970